Current:Home > FinanceUnanimous Supreme Court preserves access to widely used abortion medication -MacroWatch
Unanimous Supreme Court preserves access to widely used abortion medication
NovaQuant Quantitative Think Tank Center View
Date:2025-04-11 12:00:39
Live updates: Follow AP’s coverage of the Supreme Court’s decision to preserve access to mifepristone.
WASHINGTON (AP) — The Supreme Court on Thursday unanimously preserved access to a medication that was used in nearly two-thirds of all abortions in the U.S. last year, in the court’s first abortion decision since conservative justices overturned Roe v. Wade two years ago.
The justices ruled that abortion opponents lacked the legal right to sue over the federal Food and Drug Administration’s approval of the medication, mifepristone, and the FDA’s subsequent actions to ease access to it.
The case had threatened to restrict access to mifepristone across the country, including in states where abortion remains legal.
Justice Brett Kavanaugh wrote for the court that “federal courts are the wrong forum for addressing the plaintiffs’ concerns about FDA’s actions.” Kavanaugh was part of the majority to overturn Roe.
The high court is separately considering another abortion case, about whether a federal law on emergency treatment at hospitals overrides state abortion bans in rare emergency cases in which a pregnant patient’s health is at serious risk.
More than 6 million people have used mifepristone since 2000. Mifepristone blocks the hormone progesterone and primes the uterus to respond to the contraction-causing effect of a second drug, misoprostol. The two-drug regimen has been used to end a pregnancy through 10 weeks gestation.
Health care providers have said that if mifepristone is no longer available or is too hard to obtain, they would switch to using only misoprostol, which is somewhat less effective in ending pregnancies.
President Joe Biden’s administration and drug manufacturers had warned that siding with abortion opponents in this case could undermine the FDA’s drug approval process beyond the abortion context by inviting judges to second-guess the agency’s scientific judgments. The Democratic administration and New York-based Danco Laboratories, which makes mifepristone, argued that the drug is among the safest the FDA has ever approved.
The decision “safeguards access to a drug that has decades of safe and effective use,” Danco spokeswoman Abigail Long said in a statement.
The abortion opponents argued in court papers that the FDA’s decisions in 2016 and 2021 to relax restrictions on getting the drug were unreasonable and “jeopardize women’s health across the nation.”
Kavanaugh acknowledged what he described as the opponents’ “sincere legal, moral, ideological, and policy objections to elective abortion and to FDA’s relaxed regulation of mifepristone.”
But he said they went to the wrong forum and should instead direct their energies to persuading lawmakers and regulators to make changes.
Those comments pointed to the stakes of the 2024 election and the possibility that an FDA commissioner appointed by Republican Donald Trump, if he wins the White House, could consider tightening access to mifepristone.
The mifepristone case began five months after the Supreme Court overturned Roe. Abortion opponents initially won a sweeping ruling nearly a year ago from U.S. District Judge Matthew Kacsmaryk, a Trump nominee in Texas, which would have revoked the drug’s approval entirely. The 5th U.S. Circuit Court of Appeals left intact the FDA’s initial approval of mifepristone. But it would reverse changes regulators made in 2016 and 2021 that eased some conditions for administering the drug.
The Supreme Court put the appeals court’s modified ruling on hold, then agreed to hear the case, though Justices Samuel Alito, the author of the decision overturning Roe, and Clarence Thomas would have allowed some restrictions to take effect while the case proceeded.
___
Follow the AP’s coverage of the U.S. Supreme Court at https://apnews.com/hub/us-supreme-court.
veryGood! (164)
Related
- A South Texas lawmaker’s 15
- USA vs. France takeaways: What Americans' loss in Paris Olympics opener taught us
- North Korean charged in ransomware attacks on American hospitals
- Watch Billie Eilish prank call Margot Robbie, Dakota Johnson: 'I could throw up'
- New Zealand official reverses visa refusal for US conservative influencer Candace Owens
- Polyamory, pregnancy and the truth about what happens when a baby enters the picture
- Squatter gets 40 years for illegally taking over Panama City Beach condo in Florida
- Company says manufacturing problem was behind wind turbine blade breaking off Nantucket Island
- DoorDash steps up driver ID checks after traffic safety complaints
- S&P and Nasdaq close at multiweek lows as Tesla, Alphabet weigh heavily
Ranking
- EU countries double down on a halt to Syrian asylum claims but will not yet send people back
- OpenAI tests ChatGPT-powered search engine that could compete with Google
- Man arrested on arson charge after Arizona wildfire destroyed 21 homes, caused evacuations
- How Kristin Cavallari's Inner Circle Really Feels About Her 13-Year Age Gap With Boyfriend Mark Estes
- US wholesale inflation accelerated in November in sign that some price pressures remain elevated
- USA vs. France takeaways: What Americans' loss in Paris Olympics opener taught us
- CrowdStrike shares details on cause of global tech outage
- Screen time can be safer for your kids with these devices
Recommendation
The company planning a successor to Concorde makes its first supersonic test
Kit Harington Makes Surprise Return to Game of Thrones Universe
Alicia Vikander Privately Welcomed Another Baby With Husband Michael Fassbender
USA vs. France takeaways: What Americans' loss in Paris Olympics opener taught us
See you latte: Starbucks plans to cut 30% of its menu
Recalled Diamond Shruumz edibles now linked to two possible deaths and cases in 28 states
A man got third-degree burns walking on blazing hot sand dunes in Death Valley, rangers say
USWNT starting XI vs. Zambia: Emma Hayes' first lineup for 2024 Paris Olympics